Emerging blood-based biomarkers for detection of gastric cancer
Emerging blood-based biomarkers for detection of gastric cancer
复制标题
DOI：
10.3748/wjg.v21.i41.11636
复制
发表时间：
2015-11-07
影响因子：
4.3
通讯作者：
Line, Aija
中科院分区：
文献类型：
--
作者：
Kalnina, Zane;Meistere, Irena;Line, Aija
早期发现和有效监测肿瘤动态是减少疾病负担和死亡率以及改善胃癌患者管理的先决条件。用于检测早期胃癌的血液生物标志物检测对于全人群或基于风险群体的筛查计划都具有重要意义，而反映肿瘤基因组成和动态的循环生物标志物将允许监测治疗效果，预测复发和评估肿瘤的遗传异质性。最近对血液中GC生物标志物的研究已经鉴定出了各种各样的癌症相关分子，包括各种蛋白质、针对肿瘤相关抗原的自身抗体、无细胞DNA片段、mrna和各种非编码rna、循环肿瘤细胞和癌症来源的细胞外囊泡。每种类型的生物标志物提供了不同的疾病状态信息，具有不同的优点和缺点，以及不同的临床用途。本文综述了近年来血液GC生物标志物的研究进展，讨论了各种类型生物标志物的起源及其临床应用，以及开发用于临床的生物标志物检测的技术挑战。
Early detection and efficient monitoring of tumor dynamics are prerequisites for reducing disease burden and mortality, and for improving the management of patients with gastric cancer (GC). Blood-based biomarker assays for the detection of early-stage GC could be of great relevance both for population-wide or risk group-based screening programs, while circulating biomarkers that reflect the genetic make-up and dynamics of the tumor would allow monitoring of treatment efficacy, predict recurrences and assess the genetic heterogeneity of the tumor. Recent research to identify blood-based biomarkers of GC has resulted in the identification of a wide variety of cancer-associated molecules, including various proteins, autoantibodies against tumor associated antigens, cell-free DNA fragments, mRNAs and various non-coding RNAs, circulating tumor cells and cancer-derived extracellular vesicles. Each type of these biomarkers provides different information on the disease status, has different advantages and disadvantages, and distinct clinical usefulness. In the current review, we summarize the recent developments in blood-based GC biomarker discovery, discuss the origin of various types of biomarkers and their clinical usefulness and the technological challenges in the development of biomarker assays for clinical use.